These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 22077553)

  • 1. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.
    Staser K; Yang FC; Clapp DW
    Annu Rev Pathol; 2012; 7():469-95. PubMed ID: 22077553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells.
    Staser K; Yang FC; Clapp DW
    Curr Opin Hematol; 2010 Jul; 17(4):287-93. PubMed ID: 20571392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast cells and the neurofibroma microenvironment.
    Staser K; Yang FC; Clapp DW
    Blood; 2010 Jul; 116(2):157-64. PubMed ID: 20233971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.
    Yang FC; Ingram DA; Chen S; Zhu Y; Yuan J; Li X; Yang X; Knowles S; Horn W; Li Y; Zhang S; Yang Y; Vakili ST; Yu M; Burns D; Robertson K; Hutchins G; Parada LF; Clapp DW
    Cell; 2008 Oct; 135(3):437-48. PubMed ID: 18984156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
    Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
    Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for plexiform neurofibromas in patients with NF1.
    Ardern-Holmes SL; North KN
    Lancet Oncol; 2012 Dec; 13(12):1175-6. PubMed ID: 23099008
    [No Abstract]   [Full Text] [Related]  

  • 7. Experimental therapy for neurofibromatosis I shows promise: cancer drug shrinks some plexiform neuromas.
    Am J Med Genet A; 2013 Feb; 161A(2):viii-ix. PubMed ID: 23348988
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi.
    Hida T; Idogawa M; Okura M; Sugita S; Sugawara T; Sasaki Y; Tokino T; Yamashita T; Uhara H
    J Dermatol; 2020 Jun; 47(6):658-662. PubMed ID: 32246533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.
    Yang FC; Chen S; Clegg T; Li X; Morgan T; Estwick SA; Yuan J; Khalaf W; Burgin S; Travers J; Parada LF; Ingram DA; Clapp DW
    Hum Mol Genet; 2006 Aug; 15(16):2421-37. PubMed ID: 16835260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of nerve microenvironment for neurofibroma development.
    Liao CP; Pradhan S; Chen Z; Patel AJ; Booker RC; Le LQ
    Oncotarget; 2016 Sep; 7(38):61500-61508. PubMed ID: 27517146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
    Armstrong AE; Rhodes SD; Smith A; Chen S; Bessler W; Ferguson MJ; Jiang L; Li X; Yuan J; Yang X; Yang FC; Robertson KA; Ingram DA; Blakeley JO; Clapp DW
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28372. PubMed ID: 32459399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
    Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
    Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating current basic research into future therapies for neurofibromatosis type 1.
    Brosseau JP; Liao CP; Le LQ
    Br J Cancer; 2020 Jul; 123(2):178-186. PubMed ID: 32439933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
    Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
    Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene.
    Däschner K; Assum G; Eisenbarth I; Krone W; Hoffmeyer S; Wortmann S; Heymer B; Kehrer-Sawatzki H
    Biochem Biophys Res Commun; 1997 May; 234(2):346-50. PubMed ID: 9177273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas.
    Karmazyn B; Cohen MD; Jennings SG; Robertson KA
    Pediatr Radiol; 2012 Oct; 42(10):1218-22. PubMed ID: 22722872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
    Yu Y; Choi K; Wu J; Andreassen PR; Dexheimer PJ; Keddache M; Brems H; Spinner RJ; Cancelas JA; Martin LJ; Wallace MR; Legius E; Vogel KS; Ratner N
    Acta Neuropathol; 2020 Jan; 139(1):157-174. PubMed ID: 31664505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Giant plexiform neurofibroma in a patient with neurofibromatosis type I.
    Rallis E; Ragiadakou D
    Dermatol Online J; 2009 May; 15(5):7. PubMed ID: 19624985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.